Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03213522
Other study ID # CSMC 2016-14
Secondary ID
Status Recruiting
Phase N/A
First received April 17, 2017
Last updated July 7, 2017
Start date April 10, 2017
Est. completion date April 9, 2018

Study information

Verified date July 2017
Source CentraState Medical Center
Contact Danielle T Robbins, DPT
Phone 7322942700
Email drobbins@centrastate.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the efficacy of CST for the treatment of LUTS in patients with MS and evaluate the acute effects compared to PFPT.

A. Objectives To examine the effect of CST as compared to PFPT on QOL, SEMG resting biofeedback readings, and PVR ultrasonography measures in patients with MS and LUTS.

B. Hypotheses / Research Question(s) It is hypothesized that patients who receive CST will demonstrate improved QOL, bladder control and ability to empty bladder as compared to those who receive PFPT.


Description:

The purpose of this study is to determine if Craniosacral Therapy is an effective therapy for treating bladder dysfunction in patients with Multiple Sclerosis (MS). It will be compared to standard care for the treatment of bladder dysfunction, which is Pelvic Floor Physical Therapy. Bladder dysfunctions are extremely common in patients with Multiple Sclerosis. One of the most common symptoms of bladder dysfunction is called over-active bladder. Over- active bladder can be described by increased urges to urinate and frequency of urination, especially at night. Other common symptoms are: leakage of urine, with or without activity; inability to hold urine; and a decreased ability to empty bladder when urinating.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date April 9, 2018
Est. primary completion date April 9, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Diagnosis of Multiple Sclerosis

- Currently have the following symptoms for at least three (3) months or longer: frequent urination, increased urge to urinate, nighttime urination, loss/leakage of urine with or without activity, and/or problems emptying your bladder.

Exclusion Criteria:

- Unable or unwilling to give consent to be treated

- Unable or unwilling to cover your portion of physical therapy treatment (i.e. co-pays and/or deductibles)

- Cannot speak or read English

- Have NOT had any urinary symptoms for at least three (3) months

- Do not have Multiple Sclerosis; or have NOT been diagnosed with Multiple Sclerosis

- Take medication to treat your urinary symptoms; or have taken medication in the past three (3) months to treat your urinary symptoms

- Use an indwelling catheter (i.e. tube inserted into your bladder for continuous urine drainage); or you require intermittent catheterization

- Currently are experiencing any of the following: shooting or radiating pain in your back or abdomen; pain that is not relieved with body position and/or medication; nausea; decreased appetite; pain with bowel movements or urination; and/or any symptom that is new and/or of unexplained onset (i.e. you do not know why it started or when it started)

- Currently have cancer/tumors (i.e. tumors in the spine, brain, pelvis, etc.) and/or aneurysms (i.e. abdominal aortic aneurysm)

- Received Botox injections in the past three (3) months

- Received Pelvic Floor Physical Therapy and/or Craniosacral Therapy in the past three (3) months

Study Design


Intervention

Procedure:
Pelvic Floor Physical Therapy
Educating the PFPT group on therapeutic exercise, which includes, but not limited to, the pelvic brace, pelvic floor muscle exercise, and diaphragmatic breathing. If the patient is presenting with hypertonia of lower extremity muscles and/or muscles connecting to or part of the pelvic floor, the patient may be instructed on gentle static stretching and/or treated with passive stretching and diaphragmatic breathing.
Craniosacral Therapy
Modified Upledger Institute 10-step protocol.

Locations

Country Name City State
United States CentraState Medical Center Freehold New Jersey

Sponsors (1)

Lead Sponsor Collaborator
CentraState Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary PFDI-20 Pelvic floor distress inventory self-report questionnaire Change from baseline PFDI-20 after six weeks of intervention
Primary PFIQ-7 Pelvic floor incontinence questionnaire self-report Change from baseline PFIQ-7 after six weeks of intervention
Secondary MSQOL-54 Multiple Sclerosis Quality of Life self-report questionnaire Change from baseline MSQOL-54 after six weeks of intervention
Secondary Post void residual volume PVR measurement Change from baseline PVR after six weeks of intervention
Secondary Resting SEMG surface electromyographic reading, resting only Change from baseline Resting SEMG after six weeks of intervention
Secondary Systolic BP blood pressure Change from baseline Systolic BP after six weeks of intervention
Secondary Systolic BP blood pressure Change from pre-intervention to post-intervention at each of six intervention sessions
Secondary Diastolic BP blood pressure Change from baseline Diastolic BP after six weeks of intervention
Secondary Diastolic BP blood pressure Change from pre-intervention to post-intervention at each of six intervention sessions
Secondary Pulse pulse Change from pre-intervention to post-intervention at each of six intervention sessions
Secondary Pulse pulse Change from baseline Pulse after six weeks of intervention
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT02845635 - MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis